{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:43:07Z","timestamp":1790707387500,"version":"4.1.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T00:00:00Z","timestamp":1673395200000},"content-version":"vor","delay-in-days":2293,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["mp.uscap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Modern Pathology"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1038\/modpathol.2016.130","type":"journal-article","created":{"date-parts":[[2016,7,22]],"date-time":"2016-07-22T07:45:26Z","timestamp":1469173526000},"page":"1200-1211","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"title":["EBV-negative monomorphic B-cell post-transplant lymphoproliferative disorders are pathologically distinct from EBV-positive cases and frequently contain TP53 mutations"],"prefix":"10.1016","volume":"29","author":[{"given":"Elizabeth L","family":"Courville","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Yohe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Chou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Nardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandr","family":"Lazaryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beenu","family":"Thakral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew C","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith A","family":"Ferry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aliyah R","family":"Sohani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/modpathol.2016.130_bib1","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s11899-013-0162-5","article-title":"Post-transplant lymphoproliferative disease (PTLD): risk factors, diagnosis, and current treatment strategies","volume":"8","author":"Al-Mansour","year":"2013","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1038\/modpathol.2016.130_bib2","series-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","first-page":"343","article-title":"Post-transplant lymphoproliferative disorders","author":"Swerdlow","year":"2008"},{"key":"10.1038\/modpathol.2016.130_bib3","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1053\/j.semdp.2012.08.005","article-title":"Immunosuppressive and immunomodulatory therapy-associated lymphoproliferative disorders","volume":"30","author":"Bagg","year":"2013","journal-title":"Semin Diagn Pathol"},{"key":"10.1038\/modpathol.2016.130_bib4","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/00000478-200003000-00006","article-title":"Epstein-Barr virus-negative post-transplant lymphoproliferative disorders: a distinct entity?","volume":"24","author":"Nelson","year":"2000","journal-title":"Am J Surg Pathol"},{"key":"10.1038\/modpathol.2016.130_bib5","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1200\/JCO.1998.16.6.2052","article-title":"Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: a distinct entity?","volume":"16","author":"Leblond","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1038\/modpathol.2016.130_bib6","doi-asserted-by":"crossref","first-page":"3775","DOI":"10.1182\/blood-2003-05-1683","article-title":"Molecular histogenesis of posttransplantation lymphoproliferative disorders","volume":"102","author":"Capello","year":"2003","journal-title":"Blood"},{"key":"10.1038\/modpathol.2016.130_bib7","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1111\/ajt.12196","article-title":"Gene expression profiling reveals clear differences between EBV-positive and EBV-negative posttransplant lymphoproliferative disorders","volume":"13","author":"Morscio","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1038\/modpathol.2016.130_bib8","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","volume":"103","author":"Hans","year":"2004","journal-title":"Blood"},{"key":"10.1038\/modpathol.2016.130_bib9","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1309\/AJCPPHMZ6VHF0WQV","article-title":"p53 expression is a strong marker of inferior survival in de novo diffuse large B-cell lymphoma and may have enhanced negative effect with MYC coexpression: a single institutional clinicopathologic study","volume":"141","author":"Xie","year":"2014","journal-title":"Am J Clin Pathol"},{"key":"10.1038\/modpathol.2016.130_bib10","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1182\/blood-2012-10-461848","article-title":"CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study","volume":"121","author":"Hu","year":"2013","journal-title":"Blood"},{"key":"10.1038\/modpathol.2016.130_bib11","doi-asserted-by":"crossref","first-page":"4021","DOI":"10.1182\/blood-2012-10-460063","article-title":"MYC\/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program","volume":"121","author":"Hu","year":"2013","journal-title":"Blood"},{"key":"10.1038\/modpathol.2016.130_bib12","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1182\/blood-2012-06-435842","article-title":"MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma","volume":"121","author":"Horn","year":"2013","journal-title":"Blood"},{"key":"10.1038\/modpathol.2016.130_bib13","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1200\/JCO.2011.41.0985","article-title":"Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone","volume":"30","author":"Johnson","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1038\/modpathol.2016.130_bib14","doi-asserted-by":"crossref","first-page":"7785","DOI":"10.1158\/1078-0432.CCR-11-0267","article-title":"BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximab","volume":"17","author":"Iqbal","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1038\/modpathol.2016.130_bib15","doi-asserted-by":"crossref","first-page":"3986","DOI":"10.1182\/blood-2012-05-433334","article-title":"Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study","volume":"120","author":"Xu-Monette","year":"2012","journal-title":"Blood"},{"key":"10.1038\/modpathol.2016.130_bib16","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1080\/10428190802239162","article-title":"Clinical and pathological prognostic markers for survival in adult patients with post-transplant lymphoproliferative disorders in solid transplant","volume":"49","author":"Oton","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1038\/modpathol.2016.130_bib17","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1097\/01.pas.0000213317.59176.d2","article-title":"Impact of Epstein-Barr virus in monomorphic B-cell posttransplant lymphoproliferative disorders: a histogenetic study","volume":"30","author":"Johnson","year":"2006","journal-title":"Am J Surg Pathol"},{"key":"10.1038\/modpathol.2016.130_bib18","doi-asserted-by":"crossref","first-page":"669","DOI":"10.3109\/0284186X.2013.844853","article-title":"A population-based study of 135 lymphomas after solid organ transplantation: the role of Epstein-Barr virus, hepatitis C and diffuse large B-cell lymphoma subtype in clinical presentation and survival","volume":"53","author":"Kinch","year":"2014","journal-title":"Acta Oncol"},{"key":"10.1038\/modpathol.2016.130_bib19","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s13073-015-0251-2","article-title":"ScanIndel: a hybrid framework for indel detection via gapped alignment, split reads and de novo assembly","volume":"7","author":"Yang","year":"2015","journal-title":"Genome Med"},{"key":"10.1038\/modpathol.2016.130_bib20","doi-asserted-by":"crossref","first-page":"D805","DOI":"10.1093\/nar\/gku1075","article-title":"COSMIC: exploring the world's knowledge of somatic mutations in human cancer","volume":"43","author":"Forbes","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"10.1038\/modpathol.2016.130_bib21","doi-asserted-by":"crossref","first-page":"3088","DOI":"10.1182\/blood-2008-01-129783","article-title":"Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study","volume":"112","author":"Young","year":"2008","journal-title":"Blood"},{"key":"10.1038\/modpathol.2016.130_bib22","doi-asserted-by":"crossref","first-page":"4396","DOI":"10.1182\/blood-2007-02-072082","article-title":"Mutations in the DNA-binding codons of TP53, which are associated with decreased expression of TRAILreceptor-2, predict for poor survival in diffuse large B-cell lymphoma","volume":"110","author":"Young","year":"2007","journal-title":"Blood"},{"key":"10.1038\/modpathol.2016.130_bib23","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/j.1365-2559.2005.02222.x","article-title":"Expression and prognostic implications of cell cycle regulatory molecules, p16, p21, p27, p14 and p53 in germinal centre and non-germinal centre B-like diffuse large B-cell lymphomas","volume":"47","author":"Paik","year":"2005","journal-title":"Histopathology"},{"key":"10.1038\/modpathol.2016.130_bib24","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1309\/YHFE-R65B-D3LK-3GGV","article-title":"Expression of c-Myc and p53 correlates with clinical outcome in diffuse large B-cell lymphomas","volume":"113","author":"Chang","year":"2000","journal-title":"Am J Clin Pathol"},{"key":"10.1038\/modpathol.2016.130_bib25","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1182\/blood.V85.2.552.552","article-title":"Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders","volume":"85","author":"Knowles","year":"1995","journal-title":"Blood"},{"key":"10.1038\/modpathol.2016.130_bib26","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/hon.751","article-title":"Post-transplant lymphoproliferative disorders: molecular basis of disease histogenesis and pathogenesis","volume":"23","author":"Capello","year":"2005","journal-title":"Hematol Oncol"},{"key":"10.1038\/modpathol.2016.130_bib27","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/humu.10032","article-title":"Integrating mutation data and structural analysis of the TP53 tumor-suppressor protein","volume":"19","author":"Martin","year":"2002","journal-title":"Hum Mutat"},{"key":"10.1038\/modpathol.2016.130_bib28","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/humu.20495","article-title":"Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database","volume":"28","author":"Petitjean","year":"2007","journal-title":"Hum Mutat"},{"key":"10.1038\/modpathol.2016.130_bib29","first-page":"e2009018","article-title":"Post-transplant lymphoproliferative disorders: role of viral infection, genetic lesions and antigen stimulation in the pathogenesis of the disease","volume":"1","author":"Capello","year":"2009","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"10.1038\/modpathol.2016.130_bib30","doi-asserted-by":"crossref","first-page":"5002","DOI":"10.1073\/pnas.0400945101","article-title":"The mutator pathway is a feature of immunodeficiency-related lymphomas","volume":"101","author":"Duval","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1038\/modpathol.2016.130_bib31","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1365-2141.1995.tb05252.x","article-title":"Bcl6\/Laz3 rearrangements in post-transplant lymphoproliferative disorders","volume":"91","author":"Delecluse","year":"1995","journal-title":"Br J Haematol"},{"key":"10.1038\/modpathol.2016.130_bib32","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1182\/blood.V92.7.2294","article-title":"BCL-6 gene mutations in posttransplantation lymphoproliferative disorders predict response to therapy and clinical outcome","volume":"92","author":"Cesarman","year":"1998","journal-title":"Blood"},{"key":"10.1038\/modpathol.2016.130_bib33","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1046\/j.1365-2141.2003.04644.x","article-title":"Frequent aberrant promoter hypermethylation of O6-methylguanine-DNA methyltransferase and death-associated protein kinase genes in immunodeficiency-related lymphomas","volume":"123","author":"Rossi","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1038\/modpathol.2016.130_bib34","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1002\/path.2555","article-title":"Molecular characterization of post-transplant lymphoproliferative disorders of donor origin occurring in liver transplant recipients","volume":"218","author":"Capello","year":"2009","journal-title":"J Pathol"},{"key":"10.1038\/modpathol.2016.130_bib35","doi-asserted-by":"crossref","first-page":"3884","DOI":"10.1002\/cncr.28899","article-title":"MYC-associated and double-hit lymphomas: A review of pathobiology, prognosis, and therapeutic approaches","volume":"120","author":"Petrich","year":"2014","journal-title":"Cancer"},{"key":"10.1038\/modpathol.2016.130_bib36","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1200\/JCO.2009.26.3947","article-title":"Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab","volume":"28","author":"Barrans","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1038\/modpathol.2016.130_bib37","first-page":"53","article-title":"Post-transplant lymphoproliferative disorders. Molecular analysis of histogenesis and pathogenesis","volume":"95","author":"Capello","year":"2004","journal-title":"Minerva Med"},{"key":"10.1038\/modpathol.2016.130_bib38","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1111\/j.1600-6143.2011.03499.x","article-title":"Epstein-Barr Virus-related post-transplant lymphoproliferative disorders: pathogenetic insights for targeted therapy","volume":"11","author":"Nourse","year":"2011","journal-title":"Am J Transplant"},{"key":"10.1038\/modpathol.2016.130_bib39","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1200\/JCO.2010.30.0368","article-title":"Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab","volume":"29","author":"Meyer","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1038\/modpathol.2016.130_bib40","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1056\/NEJMoa0802885","article-title":"Stromal gene signatures in large-B-cell lymphomas","volume":"359","author":"Lenz","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1038\/modpathol.2016.130_bib41","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature"},{"key":"10.1038\/modpathol.2016.130_bib42","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1182\/blood-2013-11-536433","article-title":"Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue","volume":"123","author":"Scott","year":"2014","journal-title":"Blood"},{"key":"10.1038\/modpathol.2016.130_bib43","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1200\/JCO.2005.03.4264","article-title":"BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma","volume":"24","author":"Iqbal","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1038\/modpathol.2016.130_bib44","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/978-3-319-13150-4_13","article-title":"Post-transplant lymphoproliferative disorders","volume":"165","author":"Singavi","year":"2015","journal-title":"Cancer Treat Res"},{"key":"10.1038\/modpathol.2016.130_bib45","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1007\/s11864-011-0177-x","article-title":"Post transplant lymphoproliferative disorders: risk, classification, and therapeutic recommendations","volume":"13","author":"Jagadeesh","year":"2012","journal-title":"Curr Treat Options Oncol"},{"key":"10.1038\/modpathol.2016.130_bib46","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1111\/ajt.12211","article-title":"Primary CNS posttransplant lymphoproliferative disease (PTLD): an international report of 84 cases in the modern era","volume":"13","author":"Evens","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1038\/modpathol.2016.130_bib47","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1309\/DW2TW2087BXL2BRK","article-title":"Histogenetic phenotypes of B cells in posttransplant lymphoproliferative disorders by immunohistochemical analysis correlate with transplant type: solid organ vs hematopoietic stem cell transplantation","volume":"123","author":"Novoa-Takara","year":"2005","journal-title":"Am J Clin Pathol"},{"key":"10.1038\/modpathol.2016.130_bib48","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/bmt.2013.96","article-title":"EBV-induced post transplant lymphoproliferative disorders: a persisting challenge in allogeneic hematopoetic SCT","volume":"49","author":"Rasche","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"10.1038\/modpathol.2016.130_bib49","doi-asserted-by":"crossref","first-page":"4992","DOI":"10.1182\/blood-2008-09-178046","article-title":"Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation","volume":"113","author":"Landgren","year":"2009","journal-title":"Blood"}],"container-title":["Modern Pathology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/modpathol2016130.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/modpathol2016130","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395222015381?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395222015381?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/modpathol2016130.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T00:50:08Z","timestamp":1760230208000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0893395222015381"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":49,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["S0893395222015381"],"URL":"https:\/\/doi.org\/10.1038\/modpathol.2016.130","relation":{},"ISSN":["0893-3952"],"issn-type":[{"value":"0893-3952","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"EBV-negative monomorphic B-cell post-transplant lymphoproliferative disorders are pathologically distinct from EBV-positive cases and frequently contain TP53 mutations","name":"articletitle","label":"Article Title"},{"value":"Modern Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1038\/modpathol.2016.130","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 United States & Canadian Academy of Pathology.","name":"copyright","label":"Copyright"}]}}